- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03478592
Assessment of the New Automated Vitrification System "GAVI" for Early Cleaved Embryos Cryopreservation (GAVI)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The last decade has seen a development of a new cryopreservation technique called vitrification. Despite a lack of randomized control trials comparing slow-freezing and vitrification, vitrification seems to show better recovery rates and pregnancy outcomes. However vitrification is a manual, labour-intensive and highly skilled procedure, results can vary between embryologists and clinics. The GAVI system, an automation instrument with a novel closed system device has been developed. The present study would like to assess the outcomes for embryos automatically vitrification processed with the GAVI system compared with those processed with conventional reference technique of slow freezing.
The meta-analysis comparing the cryopreservation of human embryos by vitrification or slow-freezing suggested that more well design studies as randomized trials are necessary to identify the most successful method for cryopreservation. The efficacy of the vitrification with the GAVI system will be compared with the conventional slow freezing method through a randomized control trial. Couples in IVF attempt will be randomized at the day of embryo cryopreservation by the biologist. Supernumerary frozen embryos will be thawed and transferred in utero in case of failure of the "fresh" embryo transfer. The outcomes of the thawing and frozen/thawed embryo transfer will be assessed. In the two groups, the patients will benefit of the standard IVF procedures applied in the Assisted Reproductive Technologies center of Toulouse.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Toulouse, France, 31059
- Hospital University of Toulouse
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Couple whose age is > 18 years and who are included in a IVF procedure with the possibility to cryopreserve embryos according to criteria applied at the hospital of Toulouse
- Signed informed consent by both partners in a couple
- Affiliation to a social security scheme for both partners of the couple
Exclusion Criteria:
- Couples who does not meet current requirements described by the bioethics law for accession to the ART procedure
- Positive plasma viral load for HIV, hepatitis C virus or hepatitis B virus during the year before the inclusion in one of the couple.
- One of the two partners (or both) is (are) in safeguarding justice, under guardianship or trusteeship.
- Couple included in another interventional study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: reference technique slow freezing
In reference technique slow freezing arm, embryon will be frozen with the conventional slow freezing procedure with the Freezal device apply a slow decreasing in temperature with moderate cryoprotector concentration
|
Slow-freezing procedure is the reference technique, actually use at the Toulouse hospital, to cryopreserve embryos.
Embryon are frozen with a slow freezing.
|
|
Experimental: vitrification technique
In vitrification technique arm, embryon will be frozen with automated vitrification system
|
Vitrification is the new technique to freeze embryons.
In this study, the GAVI system will be use for for embryos automatically vitrification
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Implantation rate of frozen/thawed embryos
Time Frame: 1 month
|
The number of implantation embryo with cardiac activity in reference technique and in vitrification technic
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of intact blastomeres after thawing
Time Frame: 1 month
|
It will be measured by microscopic evaluation by a biologist or an IVF laboratory technician at the time of thawing, routine very simple laboratory to do because at this early embryonic stage there are few cells: 4 to 8 cells and they are well individualized.
|
1 month
|
|
Implantation rate of transferred embryos.
Time Frame: 1 month
|
number of implantation of transferred embryos in both technique
|
1 month
|
|
Live birth rates
Time Frame: 9 months after the implantation
|
Number of live birth for reference technique and for vitrification technique
|
9 months after the implantation
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Roger Léandri, MD, University Hospital, Toulouse
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- RC31/16/8766
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fertility Disorders
-
Charite University, Berlin, GermanyKarl and Veronica Carstens FoundationTerminatedFertility Issues | Fertility Disorders | IVF | Sub Fertility, Female | Sub-fertilityGermany
-
FairtilityRecruitingData Collection Protocol for the Development of CHLOE-OQ, an AI Model for Assessing Oocytes Quality.Fertility DisordersUnited States
-
ProbiSearch SLRecruitingFertility DisordersSpain, Portugal
-
Assiut UniversityRecruiting
-
Instituto BernabeuRecruiting
-
Quanovate Tech Inc.Completed
-
Centre Hospitalier Intercommunal CreteilIBSA Institut Biochimique SA; Laboratoires GenévrierCompleted
-
SPD Development Company LimitedCompleted
-
Institut Universitari DexeusCompletedFertility DisordersSpain, Vietnam
-
University of Turin, ItalyCompleted
Clinical Trials on reference technique
-
Mirna ashraf anis heneenRecruitingEdentulous Jaw | Dental Implantation, Endosseous | Prosthodontics | Dental Prosthesis, Implant-SupportedEgypt
-
Artromedical Konrad Malinowski ClinicRecruitingMeniscus; Degeneration | Meniscus Lesion | Meniscus Tear | Meniscus DisorderPoland
-
Centre Hospitalier Universitaire de NīmesBioMérieuxCompleted
-
The Affiliated Hospital of Qingdao UniversityEnrolling by invitationPharmacokinetics | SafetyChina
-
Academisch Medisch Centrum - Universiteit van Amsterdam...DexCom, Inc.CompletedDiabetes Mellitus, Type 1Netherlands
-
Nutricia ResearchCompletedGlycemic ResponseCanada
-
Sonova AGCompleted
-
JHP Pharmaceuticals LLCSyneos HealthUnknown
-
Simcere Pharmaceutical Co., LtdNot yet recruiting
-
Nutricia ResearchRecruitingGlycemic ResponseCanada